Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users

Staszewski, S.; Haberl, A.; Gute, P.; Nisius, G.; Miller, V.; Carlebach, A.

Antiviral Therapy 3(Suppl 4): 55-56

1998


ISSN/ISBN: 1359-6535
PMID: 10723511
Document Number: 489011
Human immunodeficiency virus (HIV)-infected, active intravenous drug users received once-daily therapy consisting of a combination of didanosine (2',3'-dideoxyinosine or DDI), lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine or 3TC] and nevirapine. Preliminary results for the first 24 weeks show that the regimen provides potent immunological and antiviral effects.

Document emailed within 1 workday
Secure & encrypted payments